⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23494298 | 0.74 | — | — | |
| SCHEMBL3616613 | 0.70 | — | — | |
| SCHEMBL1579416 | 0.69 | RECQL (0.37) | — | |
| SCHEMBL13505183 | 0.69 | — | — | |
| SCHEMBL135914 | 0.67 | — | — | |
| SCHEMBL424257 | 0.65 | — | — | |
| SCHEMBL15136162 | 0.64 | — | — | |
| SCHEMBL910279 | 0.64 | — | — | |
| SCHEMBL22879195 | 0.62 | — | — | |
| SCHEMBL12955381 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11970485-B2 | RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2024-04-30 | — | — | US | claimed |
| US-11964968-B2 | Compounds useful for inhibiting RET kinase | ELI LILLY AND COMPANY (US) | 2024-04-23 | — | — | US | claimed |
| EP-4273147-A1 | SUBSTITUTED SPIROLACTAMS, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2023-11-08 | — | — | EP | claimed |
| US-20230312544-A1 | COMPOUNDS USEFUL FOR INHIBITING RET KINASE | LOXO ONCOLOGY, INC. | 2023-10-05 | — | — | US | claimed |
| US-20230265085-A1 | RET KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2023-08-24 | — | — | US | claimed |
| CN-116438179-A | Pyrazole derivatives as RET kinase inhibitors | 伊莱利利公司 | 2023-07-14 | — | — | CN | claimed |
| US-11697647-B2 | RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2023-07-11 | — | — | US | claimed |
| US-11613533-B2 | Compounds useful for inhibiting RET kinase | ELI LILLY AND COMPANY (US) | 2023-03-28 | — | — | US | claimed |
| EP-4143184-A1 | COMPOUNDS USEFUL FOR INHIBITING RET KINASE | Eli Lilly and Company (US) | 2023-03-08 | — | — | EP | claimed |
| CN-115667253-A | Compounds useful for inhibition of RET kinase | 伊莱利利公司 | 2023-01-31 | — | — | CN | claimed |
| US-20220144816-A1 | RET KINASE INHIBITORS | EVOTEC INTERNATIONAL GMBH (DE) | 2022-05-12 | — | — | US | claimed |
| US-20210363140-A1 | COMPOUNDS USEFUL FOR INHIBITING RET KINASE | LOXO ONCOLOGY, INC. | 2021-11-25 | — | — | US | claimed |
| WO-2021222017-A1 | COMPOUNDS USEFUL FOR INHIBITING RET KINASE | ELI LILLY AND COMPANY (US) | 2021-11-04 | — | — | WO | claimed |
| US-11970485-B2 | RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2024-04-30 | — | — | US | disclosed |
| EP-4273147-A1 | SUBSTITUTED SPIROLACTAMS, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2023-11-08 | — | — | EP | disclosed |
| US-20230265085-A1 | RET KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2023-08-24 | — | — | US | disclosed |
| EP-2255780-A1 | PARAKERATOSIS INHIBITOR, PORE SHRINKING AGENT OR AGENT FOR PREVENTING OR IMPROVING ROUGH SKIN, AND COMPOSITION FOR EXTERNAL USE ON THE SKIN CONTAINING THE SAME | Shiseido Company, Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| CN-101267803-A | Wrinkle-improving agent | SHISEIDO CO LTD (JP) | 2008-09-17 | — | — | CN | disclosed |
| CN-101175470-A | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO CO LTD (JP) | 2008-05-07 | — | — | CN | disclosed |
| EP-1880711-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |